Atria Wealth Solutions Inc. Sells 1,333 Shares of Axon Enterprise, Inc (NASDAQ:AXON)

Atria Wealth Solutions Inc. lowered its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 39.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,088 shares of the biotechnology company’s stock after selling 1,333 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Axon Enterprise were worth $1,098,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Capital World Investors increased its stake in Axon Enterprise by 86.4% in the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company’s stock worth $1,079,145,000 after buying an additional 841,772 shares during the period. Westfield Capital Management Co. LP increased its stake in Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after buying an additional 212,931 shares during the period. GAMMA Investing LLC increased its stake in Axon Enterprise by 58,725.5% in the 1st quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company’s stock worth $402,210,000 after buying an additional 763,431 shares during the period. Northern Trust Corp increased its stake in Axon Enterprise by 19.8% in the 4th quarter. Northern Trust Corp now owns 716,926 shares of the biotechnology company’s stock worth $426,083,000 after buying an additional 118,469 shares during the period. Finally, Jennison Associates LLC increased its stake in Axon Enterprise by 23,203.7% in the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after buying an additional 611,418 shares during the period. Institutional investors own 79.08% of the company’s stock.

Insider Activity at Axon Enterprise

In other news, CAO Jennifer H. Mak sold 75 shares of the business’s stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $771.81, for a total transaction of $57,885.75. Following the transaction, the chief accounting officer owned 15,240 shares of the company’s stock, valued at approximately $11,762,384.40. The trade was a 0.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Joshua Isner sold 905 shares of the business’s stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $776.39, for a total transaction of $702,632.95. Following the transaction, the president directly owned 268,735 shares in the company, valued at approximately $208,643,166.65. The trade was a 0.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,585 shares of company stock worth $16,100,838 over the last 90 days. Corporate insiders own 5.70% of the company’s stock.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $818.69 on Tuesday. The firm has a market cap of $64.27 billion, a PE ratio of 202.15, a PEG ratio of 30.92 and a beta of 1.36. The firm has a fifty day moving average of $775.48 and a 200 day moving average of $666.90. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise, Inc has a one year low of $346.71 and a one year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.54 by $0.58. The company had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm’s revenue was up 32.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.20 EPS. As a group, research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on AXON shares. Raymond James Financial reaffirmed an “outperform” rating and issued a $855.00 price target (up previously from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. The Goldman Sachs Group raised their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a “buy” rating in a research report on Wednesday, May 14th. Needham & Company LLC set a $870.00 target price on shares of Axon Enterprise and gave the company a “buy” rating in a research report on Tuesday, August 5th. Bank of America raised their target price on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a research report on Wednesday, August 6th. Finally, Morgan Stanley set a $885.00 target price on shares of Axon Enterprise and gave the company an “overweight” rating in a research report on Friday, July 11th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus target price of $837.69.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.